Studying Early Immune Changes in Children with Immune Thrombocytopenic Purpura and Lupus
Compares immune blood findings in children with immune thrombocytopenic purpura or lupus.
Plain-language title generated from the registry record
Registry title: Modeling the Early Stages of Autoimmunity Through the Study of Immunological Thrombocytopenic Purpura and Juvenile Lupus
Key facts
- Where
- Bordeaux and Toulouse, FranceSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 18 years old?
Source: NCT07680010, who can take part
Where in France
- CHU de Bordeaux - Groupe hospitalier Pellegrin - Hôpital des enfantsBordeaux, FranceNo longer taking part
- CHU Toulouse Hôpital des EnfantsToulouse, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Bordeaux
- Trial code
- NCT07680010
- Record updated
- 17 July 2026
- Original description
Immunologic thrombocytopenic purpura (ITP) in children is a pre-lupus condition if associated with the presence of anti-nuclear antibodies (ANA), providing a unique model for understanding the natural history of autoimmunity, particularly that of systemic lupus erythematosus (SLE). The investigators will describe the shared and/or unique immunological pathways involved at diagnosis in 70 children with ITP and in 20 children with SLE, and compare them between ITP-ANA- (more often transient), ITP-ANA+ (pre-lupus condition, more often persistent) and SLERead full original descriptionShow less
Modeling the Early Stages of Autoimmunity Through the Study of Immunological Thrombocytopenic Purpura and Juvenile Lupus PRELUDE
Immunologic thrombocytopenic purpura (ITP) in children is a pre-lupus condition if associated with the presence of anti-nuclear antibodies (ANA), providing a unique model for understanding the natural history of autoimmunity, particularly that of systemic lupus erythematosus (SLE). The investigators will describe the shared and/or unique immunological pathways involved at diagnosis in 70 children with ITP and in 20 children with SLE, and compare them between ITP-ANA- (more often transient), ITP-ANA+ (pre-lupus condition, more often persistent) and SLE
Inclusion criteria:; For patients :; Child or adolescent with newly diagnosed ITP or SLE according to the specific definitions of ITP or SLE, prior to any treatment,; Over 1 and under 18 years of age at diagnosis, weighing more than 7 kg; Written consent from parents or guardians,; Patient affiliated to a social security scheme; For controls :; Over 1 and under 18 years of age at diagnosis, weighing more than 7 kg; Follow-up in the day hospital at the Bordeaux University Hospital, for a condition that does not affect the immune system; Matched on age,; Written consent from parents or guardians,; Patient affiliated to a social security scheme; Exclusion criteria:; For patients :; ITP secondary to a known cause: previous or concomitant immune deficiency, bone marrow or organ transplantation, other autoimmune disease, Evans syndrome (autoimmune hemolytic anemia or autoimmune neutropenia present at ITP diagnosis) or cancer with immunosuppressive therapy; Treatment with immunomodulation or immunosuppressants (including immunoglobulins, corticoids, hydroxychloroquine), started prior to inclusion (day of sampling); Pregnant women, women in labour and breastfeeding women; For controls :; Suffering from an immunological disease,; Infection within fifteen days prior to inclusion,; Immunomodulatory therapy; Pregnant women, women in labour and breastfeeding women.